Global Biological Drug CDMO Supply, Demand and Key Producers, 2023-2029

Global Biological Drug CDMO Supply, Demand and Key Producers, 2023-2029

The global Biological Drug CDMO market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Biological drug CDMO (Contract Development and Manufacturing Organization) is a company that specializes in the development and manufacturing of biological drugs. Biological drugs are complex molecules that are produced from living cells, and they include a wide range of products such as vaccines, monoclonal antibodies, and cell therapies.

This report studies the global Biological Drug CDMO demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Biological Drug CDMO, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Biological Drug CDMO that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Biological Drug CDMO total market, 2018-2029, (USD Million)

Global Biological Drug CDMO total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Biological Drug CDMO total market, key domestic companies and share, (USD Million)

Global Biological Drug CDMO revenue by player and market share 2018-2023, (USD Million)

Global Biological Drug CDMO total market by Type, CAGR, 2018-2029, (USD Million)

Global Biological Drug CDMO total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Biological Drug CDMO market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Samsung Biologics, Lonza, Boehringer Ingelheim, Catalent, BioCentriq, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific, Recipharm and Delpharm, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Biological Drug CDMO market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Biological Drug CDMO Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Biological Drug CDMO Market, Segmentation by Type
Innovative Drug
Listed Patent Drugs
Biosimilar

Global Biological Drug CDMO Market, Segmentation by Application
Pharmaceutical Company
Biotechnology Company

Companies Profiled:
Samsung Biologics
Lonza
Boehringer Ingelheim
Catalent
BioCentriq
FUJIFILM Diosynth Biotechnologies
Thermo Fisher Scientific
Recipharm
Delpharm
Aenova
Siegfried
WuXi Biologics
Obio Technology
Hepalink
Pharmaron
ChemPartner

Key Questions Answered

1. How big is the global Biological Drug CDMO market?

2. What is the demand of the global Biological Drug CDMO market?

3. What is the year over year growth of the global Biological Drug CDMO market?

4. What is the total value of the global Biological Drug CDMO market?

5. Who are the major players in the global Biological Drug CDMO market?

6. What are the growth factors driving the market demand?